Washington Bridge contractors say RIDOT issued flawed RFP in countersuit against state

Traffic flows in both directions on Interstate 195 on the eastbound side of the Washington Bridge on Friday, June 13, 2025, at 3:50 p.m. Demolition work that has removed much of the westbound side of the Washington Bridge is expected to be completed in December. (Rhode Island Department of Transportation Traffic Camera)
Two of the 13 firms being sued by the state for allegedly doing negligent work on the westbound Washington Bridge have filed a counterclaim, alleging the Rhode Island Department of Transportation (RIDOT) failed to tell them about a key inspection report.
The counterclaim filed by Barletta Heavy Division Inc. and Aetna Bridge Company in Providence County Superior Court Thursday argues they should have been alerted to the findings of a January 1992 report by Lichtenstein & Associates, at the time they bid for the state's $78 million contract to rehabilitate the Washington Bridge in 2021.
The 1992 report was cited by the state in its lawsuit against the firms, claiming they all should have known about deterioration in the concrete drop-in beams and signs of distress in the grout and cantilever beams that were eventually deemed a risk to the bridge's structural integrity. The westbound span on Interstate 195 was closed in December 2023 when engineers determined the bridge was at risk of collapsing.
'RIDOT knew or should have known, or ought to have known, that the Washington Bridge incorporated a unique design that limited the ability to determine its condition from visual inspections alone,' the counterclaim states.
The westbound bridge is expected to be rebuilt by November 2028 and cost up to $427 million. Chicago-headquartered Walsh Construction Company was awarded the state's contract on June 6 after two attempts by Gov. Dan McKee's administration to secure a bridge builder.
Work is scheduled to begin in July, which overlaps with the ongoing demolition of the existing bridge by Aetna, which is among the 13 firms being sued by the state. The Warwick-based contractor is expected to complete its work by the end of 2025.
Barletta and Aetna claim the state concealed the true condition of the bridge and neglected to conduct the appropriate testing ahead of issuing a request for proposals in 2021. Instead, the companies allege that they received a project scope which did not identify any structural deficiencies with the post-tensioning system.
The 1992 report called for RIDOT to perform additional radiographic and other evaluation of the Washington Bridge before any future attempts to rehabilitate the span over the Seekonk River.
'The Rhode Island Department of Transportation may have averted a costly and disastrous emergency closure of the Washington Bridge last December if it had followed recommendations in a detailed 1992 inspection report,' Barletta spokesperson Sallie Hofmeister said in an emailed statement.
Because of the state's alleged failure to investigate the bridge, Barletta and Aetna claim they were deprived of incentives available after successful completion of the initial rehabilitation project. The two firms have asked the court to issue a judgment against the state for all of its damages plus interest.
The state's initial August 2024 complaint seeks to recover damages based on alleged economic losses and physical damages, along with breaches of contracts.
RIDOT spokesperson Charles St. Martin deferred comment to Rhode Island Attorney General Peter Neronha's office, which is handling the state's case.
'Counterclaims are to be expected in a case like this,' Timothy Rondeau, a spokesperson for the AG's office, said in an emailed statement.'The state stands by the allegations in its complaint. As this is part of ongoing litigation, we have no further comment.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions

Data demonstrate the potential of TLC-6740 and TLC-1180 to induce weight loss while preserving lean mass, as monotherapy and in combination with an incretin, in obese mice MENLO PARK, Calif., June 20, 2025--(BUSINESS WIRE)--OrsoBio, Inc. ("OrsoBio" or "the Company"), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. "The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits," said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. "These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health." OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass," said Rob Myers, MD, Chief Medical Officer of OrsoBio. "Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO MiceAbstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO MiceAbstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese MiceAbstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT)This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit View source version on Contacts Media Contact Gwen GordonGwen@ Sign in to access your portfolio

2 hours ago

Conservation group makes $60M land deal to end mining threat outside Okefenokee Swamp

SAVANNAH, Ga. -- A conservation group said Friday it has reached a $60 million deal to buy land outside the Okefenokee Swamp from a mining company that environmentalists spent years battling over a proposed mine that opponents feared could irreparably damage an ecological treasure. The Conservation Fund said it will buy all 7,700 acres (31.16 square kilometers) that Alabama-based Twin Pines Minerals owns outside the Okefenokee National Wildlife Refuge in southeast Georgia, halting the company's mining plans. 'It's a big undertaking, but it was also an existential threat to the entire refuge," said Stacy Funderburke, the Conservation Fund's vice president for the central Southeast. 'We've done larger deals for larger acres, but dollar-wise this is the largest deal we've ever done in Georgia." Twin Pines President Steven Ingle confirmed the sale through a spokesman, but declined to comment further. Twin Pines of Birmingham, Alabama, had worked since 2019 to obtain permits to mine titanium dioxide, a pigment used to whiten products from paint to toothpaste, less than 3 miles (5 kilometers) from the southeastern boundary of the Okefenokee refuge near the Georgia-Florida line. The Okefenokee is the largest U.S. refuge east of the Mississippi River, covering nearly 630 square miles (1,630 square kilometers) in southeast Georgia. It is home to abundant alligators, stilt-legged wood storks and more than 400 other animal species. The mine appeared to be on the cusp of winning final approval early last year. Georgia regulators issued draft permits in February 2024 despite warnings from scientists that mining near the Okefenokee's bowl-like rim could damage its ability to hold water and increase the frequency of withering droughts. Twin Pines insisted it could mine without damaging the swamp. Regulators with the Georgia Environmental Protection Division agreed, concluding last year that mining should have a 'minimal impact' on the refuge. The decisions by Georgia regulators played an outsize role in the Twin Pines project after environmental rollbacks during President Donald Trump's first term stripped the federal government of any oversight. Advocates battling Twin Pines said there is still a potential threat to the Okefenokee, with thousands of acres of privately owned land remaining unprotected. Georgia lawmakers have batted aside multiple attempts in recent years to prohibit mining near the refuge. 'There's maybe 30,000 acres that's still vulnerable outside the Okefenokee on Trail Ridge that needs to be conserved,' said Rena Ann Peck of the Georgia River Network. Josh Marks, an Atlanta environmental attorney who fought the mining project, called the land sale 'a huge victory.' But he also called on conservationists to redouble efforts for a state law protecting the Okefenokee and to keep pressure on other companies to refrain from mining near the refuge. Funderburke said the steep purchase price for Twin Pines' land was driven largely by its mineral-rich soils that would have been highly valued by other mining operations. Reaching a deal became more urgent with the company so close to obtaining its final permits. 'It became pretty clear once a draft permit was issued last year that this was the final exit ramp' to stopping the project, Funderburke said. He said his group was closing Friday on about 40% of the property that includes the 820-acre (332-hectare) site for which Twin Pines' had sought its mining permit. The Conservation Fund plans to close on the rest by the end of July. Funderburke said he hopes there is eventually a deal for the land to pass into government ownership and protection. The U.S. Fish and Wildlife Service, which oversees the Okefenokee refuge, in January approved a plan to expand the refuge by buying up to 22,000 acres (8,900) along its perimeter from private owners. The proposal included land owned by Twin Pines. Negotiations with the Conservation Fund might explain why Twin Pines had yet to follow through on a financial commitment required before Georgia regulators could make a final decision on its mining permit. The Environmental Protection Division recently confirmed Twin Pines had been notified in February 2024 that it needed to set aside $2 million for future restoration of the mining site. The company never followed through in the 16 months before the sale was announced.

Business Insider

4 hours ago

• Business Insider

Walmart (WMT) Pays $10 Million Fine to Settle Lawsuit over Money Transfer Fraud

Walmart (WMT) has agreed to pay a $10 million fine to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest retailer of ignoring warning signs that scam artists leveraged its money transfer service to bilk consumers out of hundreds of millions of dollars. Confident Investing Starts Here: Walmart has also agreed not to process money transfers it suspects are fraudulent, or help sellers and telemarketers it believes are using its services to commit fraud. 'Electronic money transfers are one of the most common ways that scammers tell consumers to send them money, because once it's sent, it's gone for good,' said Christopher Mufarrige, director of the FTC Consumer Protection Bureau. Bentonville, Arkansas-based Walmart did not admit or deny wrongdoing in settling the case. In its complaint, the FTC accused Walmart of turning a blind eye to fraudsters who used its money transfer service to target consumers. Walmart acts as an agent for money transfers by companies such as MoneyGram and Western Union (WU). Tricksters The FTC said fraudsters used many schemes via Walmart, including impersonating Internal Revenue Service (IRS) agents, impersonating family members, and telling victims they won lotteries or sweepstakes but owed fees to collect their winnings. The judge dismissed part of the FTC's legal claim last year but let the regulator pursue most of its case. Walmart appealed that decision. The $10 million settlement effectively ends Walmart's appeal. WMT stock is up 6% this year. Is WMT Stock a Buy? average WMT price target of $109.71 implies 14.14% upside from current levels.